Several other research firms have also commented on AGL. Citigroup raised shares of Agilon Health from a "neutral" rating to a "buy" rating and upped their price target for the company from $3.25 to $5.00 in a report on Friday, April 25th. Barclays lowered their price target on shares of Agilon Health from $3.00 to $1.50 and set an "underweight" rating on the stock in a report on Wednesday, August 6th. The Goldman Sachs Group upped their price target on shares of Agilon Health from $2.50 to $5.00 and gave the company a "neutral" rating in a report on Thursday, May 8th. Evercore ISI lowered their price target on shares of Agilon Health from $5.00 to $3.00 and set an "in-line" rating on the stock in a report on Wednesday, July 9th. Finally, JMP Securities reiterated a "market perform" rating on shares of Agilon Health in a research report on Monday, April 28th. Four investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock.